- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01017185
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open label, non-randomized, multicenter, two-stage, dose escalation Phase I study evaluating single and repeated intratumoral injections of the oncolytic virus, HF10, in patients with refractory head and neck cancer, or solid tumors with cutaneous and/or superficial lesions (e.g., squamous cell carcinoma of the skin, carcinoma of the breast, and malignant melanoma).
Stage 1: Stage 1 of the study will investigate dose escalation of a single intratumoral injection over the following dose levels: 1 x 10^5 TCID50, 3 x 10^5 TCID50, 1 x 10^6 TCID50, and 1 x 10^7 TCID50. In Stage 1, it is planned that 3 patients will be enrolled per single dose cohort. Within each single dose cohort, accrual will temporarily be suspended after the first patient is entered and the patient will be followed for safety and for viral distribution and elimination. The patients in Stage 1 must be seropositive for HSV-1.
Stage 2: Stage 2 will evaluate repeated intratumoral injections of HF10 at dose levels of 1 x 10^6 TCID50/dose and 1 x 10^7 TCID50/dose. Three patients will be enrolled in each of the repeated dose cohorts. In Stage 2, the first patient treated in each repeated dose cohort must be seropositive for HSV-1. Patients in the repeated dose cohort will receive a total of four intratumoral injections in the same lesion.
Following completion of dosing in the repeated dose cohorts, an expansion cohort of three additional patients will be treated at the highest tolerated dose level.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States, 10461-2374
- Montefiore Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Texas
-
Dallas, Texas, United States, 75230
- Mary Crowley Cancer Research Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients must have histologically confirmed solid tumors that have failed standard therapies (surgery, chemotherapy, radiotherapy, or endocrine therapy) and for which no curative options exist, including, but not limited to:
- Squamous cell carcinoma of the head and neck
- Squamous cell carcinoma of the skin
- Carcinoma of the breast
- Malignant melanoma
- Patients may have had any kind and number of prior cancer therapies.
- Patients must have measurable non-visceral lesions that are evaluable by the RECIST method
- The tumor mass to be treated must be non-visceral and adequate for injection (i.e., more than 2 cm away from major vascular structures) and measurement by RECIST.
- Patients in Stage 1 must be seropositive for HSV-1.
- The first patient enrolled into each cohort in Stage 2 must be seropositive for HSV-1.
- Patients must be ≥ 18 years of age.
- Patients must have a life expectancy ≥ 12 weeks
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Patients must have adequate hepatic function, as defined as
- Total bilirubin levels ≤ 1.5 x upper limit of normal (ULN)
- AST/ALT levels ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present
- Patients must have adequate renal function as defined as serum creatinine ≤ 1.5 x ULN or creatinine clearance (calculated) ≥ 60 mL/min/1.73 m2 for patients with creatinine > 1.5 x ULN
Patients must have adequate bone marrow function, as defined as
- Absolute neutrophil count ≥ 1,500/μL and
- Platelet count ≥ 100,000/μL
- Patients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe.
- Men and women of childbearing potential must agree to use adequate contraception prior to study entry and for up to six months.
- Females of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment.
- Patients must be able to understand and willing to sign a written informed consent document.
Exclusion Criteria
- Patients receiving chemotherapy or radiotherapy within 4 weeks of injection of HF10, or adverse events > Grade 1, except alopecia, resulting from agents administered more than 4 weeks prior to HF10 injection.
- Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders.
- Patients with nasopharyngeal tumors.
- Patients with deep (below the platysma muscle layer) ulcerative tumors.
- Patients with target tumors that could potentially invade a major vascular structure(s) (e.g., innominate artery, carotid artery), based on unequivocal imaging findings, as determined by a radiologist.
- Patients with Grade ≥ 1 pre-existing neurologic abnormalities (CTCAE version 3.0).
- Patients who have been hospitalized for emergent conditions requiring inpatient evaluation, treatment or procedure during the 30 days prior to entry on study. In addition, emergent conditions requiring inpatient evaluation, treatment or procedure must have resolved or be medically stable and not severe for 30 days prior to entry on study.
- Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection. Patients will be tested for HIV during pre-treatment screening.
- Patients receiving steroids or immunosuppressive agents, e.g., for rheumatoid arthritis
- Concurrent use of any other investigational agents.
- Presence or history of central nervous system metastasis.
- Pregnant or breastfeeding women;women desiring to become pregnant within the timeframe of the study are also excluded.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oncolytic virotherapy, intratumoral injection of HF10
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of the local tumor response of the HF10-injected tumor by a modified target Response Evaluation Criteria In Solid Tumors (RECIST) method
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events, vital signs, electrocardiogram(ECG), clinical laboratory tests, and physical exercise
Time Frame: one year
|
one year
|
Histological tumor response by biopsy
Time Frame: one year
|
one year
|
Overall tumor response of the HF10-injected tumor plus additional non-injected target tumors.
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert L Ferris, MD, PhD, Division of Head and Neck Cancer Surgery, University of Pittsburgh Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Breast Neoplasms
- Head and Neck Neoplasms
- Carcinoma
- Melanoma
Other Study ID Numbers
- M06-10083
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Grupo Español Multidisciplinar de MelanomaGlaxoSmithKlineCompletedMalignant Melanoma Stage IV | Malignant Melanoma Stage IIIcSpain
-
Centre Hospitalier Universitaire de NiceUnknownMalignant Melanoma Stage III | Malignant Melanoma Stage IV
-
Hoffmann-La RocheCompletedMalignant Melanoma, CancerHungary
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsUnited States, South Africa, Croatia, Brazil, Egypt
-
Lynn E. Spitler, MDGenentech, Inc.; Celgene CorporationCompletedMetastatic Malignant MelanomaUnited States
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
Steinar AamdalTerminatedMetastatic Malignant MelanomaNorway
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsBelgium, Spain, Germany, Netherlands, Finland
-
Eli Lilly and CompanyCompletedMetastatic Malignant MelanomaUnited States
Clinical Trials on HF10
-
Rush University Medical CenterWithdrawnChronic Low-back Pain | Peripheral Neuropathy | CRPS
-
Nevro CorpActive, not recruitingPainful Diabetic NeuropathyUnited States
-
Takara Bio Inc.Completed
-
Nevro CorpActive, not recruiting
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; University of Oxford; University of Liverpool; National... and other collaboratorsUnknownChronic Low Back Pain | Neuropathic Pain | Refractory PainUnited Kingdom
-
Takara Bio Inc.CompletedMelanoma Stage IV | Melanoma Stage IIIJapan
-
Nevro CorpTerminated
-
University of UtahBristol-Myers Squibb; Takara Bio Inc.Terminated
-
Takara Bio Inc.Active, not recruitingPancreatic Cancer Stage IV | Pancreatic Cancer Stage IIIJapan
-
Takara Bio Inc.TheradexCompletedMalignant MelanomaUnited States